525 Market Street, 36th Floor
San Francisco, CA 94105-2747
This company acquires late preclinical candidates and develops them for further development. Medivation blends a unique business model with an expert team to bring promising medical technologies from the lab bench to the patient bedside. Our enzalutamide (formerly MDV3100) clinical development program addresses a large market with significant unmet medical needs. Medivation was founded by a group of experienced professionals with a long track record of working together successfully as a team in the pharmaceutical, biotechnology and medical device industries. We founded Medivation to leverage that expertise to bridge the medical product development gap between early-stage development and product launch. Through our extensive network of contacts with top-flight scientists and research institutions, we acquire early-development stage pharmaceuticals and medical devices that have promising clinical, intellectual property and commercial prospects. Using the extensive development experience and expertise of our core team, supplemented by expert consultants in relevant functions, we identify and execute the strategic pathway that will allow the most rapid, efficient and effective development. ?Our business strategy is straightforward: Build a portfolio of four to six product candidates that have the potential to be in clinical development within 12 to 18 months after acquisition; clinical studies and commercialization or, depending on the indication, conduct those activities internally. Develop those product candidates as rapidly and efficiently as possible; and Consider partnering or selling successful programs to large pharmaceutical, biotechnology or medical device companies for late-stage clinical studies and commercialization or, depending upon the indication, conduct those activities internally. Our enzalutamide development program addresses a large market with significant unmet medical needs.
Clinical Development Stage
Approved; Phase I; Phase II; Phase III